Browse All

Current Filters

CLEAR FILTER x

TITLE

OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis

Author:Newsome, Scott   Krzystanek, Ewa   Selmaj, Krzysztof   Goldstick, Lawrence   Figueiredo, Catarina   Townsend, Ben   Wolf, Christian   Zecevic, Dusanka   Giacobino, Caroline   Bortolami, Oscar   Shen, Yun-An   Kletzl, Heidemarie   Clinch, Susanne   Centonze, Diego   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.006  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  School of Health Sciences in Katowice, Katowice, Poland  Centrum Neurologii, Lodz, Poland  University of Cincinnati, Cincinnati, OH  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Lycalis sprl, Brussels, Belgium  Genentech, San Fransisco, CA  Tor Vergata University, Rome, Italy  

Indirect Treatment Comparison of Ravulizumab Versus Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

Author:Clardy, Stacey   Pittock, Sean   Aktas, Orhan   Nakahara, Jin   Isobe, Noriko   Centonze, Diego   Fam, Sami   Kielhorn, Adrian   Yu, Jeffrey   Jansen, Jeroen   Zhang, Ina   

Session Name:P10: Autoimmune Neurology: NMOSD  

Topic:Autoimmune Neurology  

Program Number:P10.005  

Author Institution:University of Utah, Salt Lake City, UT  Mayo Clinic, Rochester, MN  Heinrich Heine University, Düsseldorf, Germany  Keio University, Tokyo, Japan  Kyushu University, Fukuoka, Japan  Tor Vergata University, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA  PRECISIONheor, San Francisco, CA